BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38597129)

  • 1. Bayesian and deep-learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers.
    Abrego L; Zaikin A; Marino IP; Krivonosov MI; Jacobs I; Menon U; Gentry-Maharaj A; Blyuss O
    Cancer Med; 2024 Apr; 13(7):e7163. PubMed ID: 38597129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved early detection of ovarian cancer using longitudinal multimarker models.
    Whitwell HJ; Worthington J; Blyuss O; Gentry-Maharaj A; Ryan A; Gunu R; Kalsi J; Menon U; Jacobs I; Zaikin A; Timms JF
    Br J Cancer; 2020 Mar; 122(6):847-856. PubMed ID: 31937926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
    Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
    Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
    [No Abstract]   [Full Text] [Related]  

  • 7. HE4 combined with CA125: favorable screening tool for ovarian cancer.
    Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
    Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
    Gentry-Maharaj A; Blyuss O; Ryan A; Burnell M; Karpinskyj C; Gunu R; Kalsi JK; Dawnay A; Marino IP; Manchanda R; Lu K; Yang WL; Timms JF; Parmar M; Skates SJ; Bast RC; Jacobs IJ; Zaikin A; Menon U
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel risk models for early detection and screening of ovarian cancer.
    Russell MR; D'Amato A; Graham C; Crosbie EJ; Gentry-Maharaj A; Ryan A; Kalsi JK; Fourkala EO; Dive C; Walker M; Whetton AD; Menon U; Jacobs I; Graham RL
    Oncotarget; 2017 Jan; 8(1):785-797. PubMed ID: 27903971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
    Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.
    Blyuss O; Gentry-Maharaj A; Fourkala EO; Ryan A; Zaikin A; Menon U; Jacobs I; Timms JF
    Biomed Res Int; 2015; 2015():681416. PubMed ID: 26819954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
    Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
    Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Mukama T; Fortner RT; Katzke V; Hynes LC; Petrera A; Hauck SM; Johnson T; Schulze M; Schiborn C; Rostgaard-Hansen AL; Tjønneland A; Overvad K; Pérez MJS; Crous-Bou M; Chirlaque MD; Amiano P; Ardanaz E; Watts EL; Travis RC; Sacerdote C; Grioni S; Masala G; Signoriello S; Tumino R; Gram IT; Sandanger TM; Sartor H; Lundin E; Idahl A; Heath AK; Dossus L; Weiderpass E; Kaaks R
    Br J Cancer; 2022 May; 126(9):1301-1309. PubMed ID: 35031764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
    Xi QP; Pu DH; Lu WN
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
    Simmons AR; Clarke CH; Badgwell DB; Lu Z; Sokoll LJ; Lu KH; Zhang Z; Bast RC; Skates SJ
    Int J Gynecol Cancer; 2016 Jul; 26(6):1070-7. PubMed ID: 27206285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.